Biology Atlas

Map / The cascade

step · intermediate · partly written

Mechanism-confirmation assays

One step of the screening cascade walk-through, from disease to clinic.

What is done

Independent evidence that the compound binds this target and reaches it in a living cell. Typical pieces: surface plasmon resonance for binding rates and a dissociation constant (KD = koff/kon); isothermal titration calorimetry for Kd, stoichiometry and heat in free solution; a cellular target-engagement assay (CETSA or NanoBRET); a counter-screen against related proteins; and a structure. For ML281 the programme tested selectivity over two kinases and a panel of 83 kinases at 1 uM, where only FLT3 and KDR were inhibited 25% or more besides STK33. 1234

Reported, not yet replicated

Costs

Two public academic-core rates: surface plasmon resonance at $260 per sample for full service with 3 replicates, excluding a $500 setup (2026, subject to change); isothermal titration calorimetry at $600 for the first sample including optimisation and $300 for each further one, excluding protein (2026, undated page). Cell target-engagement assays have no public price in the records. 56

Reported, not yet replicated

Proves

That the compound physically binds this purified protein and, for cell assays, that it engages the protein in a cell. In the Takeda RIPK1 work a CETSA dose-response in HT-29 cells gave an EC50 of 6.5 nM for the lead compound against 1,100 nM for a reference, and cell EC50 tracked necroptosis inhibition (R2 = 0.9120) more closely than recombinant binding (R2 = 0.7028). 2

Reported, not yet replicated

Cannot prove

Function: a binder can be inert or bind an irrelevant site, and SPR kinetic fits can look convincing and be wrong. Cellular engagement is not benefit. Live-cell profiling of kinase inhibitors across 178 kinases found cellular ATP reduced engagement, and for crizotinib several putative targets were not engaged at a clinically relevant dose (abstract read), so purified-protein selectivity can mislead. An isothermal titration Kd from purified protein says nothing about competitors in a cell. 136

Reported, not yet replicated

Assays

Regulators require

The IND must describe the pharmacological effects and mechanism(s) of action of the drug in animals (21 CFR 312.23(a)(8)(i)); how binding and engagement were shown in vitro is not prescribed. This is our reading of the rule. 7

Our inference

ML role

Does: SPR is the arbiter of computation, as in CACHE challenge 1 where it tested predicted compounds: 73 of 1,955 bound with KD under 150 uM, and seven diverse series then held up in two orthogonal assays at 18 to 140 uM (abstract and an NSF record read). Cannot: SPR cannot say whether a binder is functional, so a model trained on its constants inherits its artefacts (our inference). 891

Reported, not yet replicated

Reports

Scenarios

Modality notes

Engagement in the right species and cell type

For an antibody the selectivity is for the human protein and cell type, so animal engagement can mislead: the 2006 TGN1412 cytokine storm was not predicted by animal testing. 101112

See: Therapeutic monoclonal antibodies, TGN1412 (anti-CD28 superagonist antibody)

Reported, not yet replicated

For siRNA, engagement is read as less target RNA and protein

Measuring success means measuring target mRNA and protein in the target tissue, plus a clinical measure, not binding strength. 131415

See: siRNA

Our inference

Still open here

Linked from

Sources

  1. Oxford Dunn School of Pathology. SPR guidelines (Sir William Dunn School of Pathology, University of Oxford). University of Oxford (2001). web, not peer reviewed; opened 2026-11-17 all records citing this
  2. Ishii, T., et al.. Ishii et al. 2017: CETSA for RIPK1 inhibitors in cells and mouse tissue, Scientific Reports. Scientific Reports (full text via Europe PMC) (2017). paper; opened 2026-11-17 all records citing this
  3. Vasta, J.D., et al.. Vasta et al. 2018: live-cell kinase inhibitor engagement profiling, Cell Chemical Biology. Cell Chemical Biology (record via Europe PMC) (2018). paper; opened 2026-11-17 all records citing this
  4. Weiwer et al.. Weiwer et al. 2012: the STK33 probe ML281 (PMC full text). PubMed Central (2012). paper; opened 2026-11-17 all records citing this
  5. Scripps Biophysics and Biochemistry Core: SPR. Scripps Research (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  6. Scripps Biophysics and Biochemistry Core: services and prices. Scripps Research (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  7. US Food and Drug Administration. IND content and format (21 CFR 312.23). Electronic Code of Federal Regulations, Title 21, Part 312 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  8. Li et al.. CACHE Challenge #1: LRRK2 WDR domain hit finding (Li et al., 2024). Journal of Chemical Information and Modeling (abstract via Europe PMC) (2024). paper; opened 2026-11-17 all records citing this
  9. NSF PAR record 10554378 for the CACHE Challenge #1 paper. NSF Public Access Repository (2024). web, not peer reviewed; opened 2026-11-17 all records citing this
  10. Suntharalingam G, et al.. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028 (2006). paper; opened 2026-11-17 all records citing this
  11. Eastwood D, Findlay L, Poole S, et al.. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161:512-526 (2010). paper; opened 2026-11-17 all records citing this
  12. Final ESG report recommends new safeguards for first-in-man trials. PharmaTimes (2006). news, not peer reviewed; opened 2026-11-17 all records citing this
  13. Foster DJ, et al.. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther (2018). paper; opened 2026-11-17 all records citing this
  14. Adams D, et al.. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med (2018). paper; opened 2026-11-17 all records citing this
  15. Judge DP, et al.. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther (2020). paper; opened 2026-11-17 all records citing this
History of this record (5)

This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Order
8
Stage
hit-to-lead
Status
partly written
Last updated
2026-11-17
Record
content/cascade/mechanism-confirmation.json